import

A new study, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, integrates patient funding programs for pharmacist teams to dramatically improve access to pharmaceutical company funding for uninsured and vulnerable cancer patients.

With the breakthrough of medical technology, various new therapies, precision medicine and medical materials have been introduced, and people have more choices, but they also face a great financial burden. We have long supported the Smart Patient Leadership Academy, which aims to cultivate patient leaders, and provides corporate volunteers, strategic consultants, resource matching and other services. With such support, the Smart Patient Leadership Academy invited experts from all walks of life to share the topic of “The Feasibility of Synergizing Health Insurance with Commercial Insurance” on 8/7, during which they discussed the current situation of health insurance and commercial insurance in Taiwan, and analyzed the current plans of other countries as a reference for future policies.

According to recent research published by JAMA Network Open, lung cancer patients who participated in the trial saw significant improvements in health-related quality of life (HRQOL) in symptom monitoring through active patient reporting systems (PROs) versus patients who received standard of care and were actively questioned by medical personnel. However, there was no significant difference between patient-reported and physician-active interventions, and no statistically significant difference was shown in overall survival. This study can extend the results to provide patients with effective patient support management for long-term symptoms without increasing the workload of healthcare professionals.

In the emerging biopharmaceutical field, the role of the Patient Support Program (PSP) is becoming increasingly important. With the improvement of medical technology and data analysis capabilities, PSPs are gradually moving away from traditional adherence management to outcome-oriented comprehensive support services with the goal of aligning the patient’s treatment context with the clinical design effect. This is also constantly changing the current situation and innovation of patient support services, driving pharmaceutical companies to shift from traditional product-oriented to service-oriented.

In the medical field, patient support services have become an important service for biopharmaceutical companies. As these services grow, the need for quantifiable benefits becomes important. Effective metrics and data analysis tools enable management to more precisely assess the effectiveness of patient support programs, ensure the rational allocation of resources, and improve patient health outcomes. Patient support services not only help improve the patient experience, but also enhance brand loyalty and market competitiveness. These services cover everything from patient education and medication management to resource support, with the aim of helping patients better manage their disease and improve treatment outcomes. Metrics such as patient engagement and satisfaction, which are commonly used to measure patient support programs, can be used to accurately assess the impact of services with the use of dynamic data analysis tools and predictive models as more real-world data is collected.

The Risk Management Plan (RMP) is a drug management strategy that takes into account drug safety and patient accessibility in line with the risk supervision actions of the Food and Drug Administration for specific marketed drugs, with reference to the management systems of advanced pharmaceutical countries such as the United States and the European Union, and the implementation of risk control by the licensed pharmaceutical companies after marketing according to the risk level of the drug, such as patient medication instructions, drug administration education for medical personnel, special risk prevention measures, etc. And regularly report to the competent government departments to effectively reduce the risk of drug use by the Chinese people.

Patient support call centers are at the heart of the patient journey, and in the past, this work was mostly scattered in clinical care, but with the complexity and individualization of medical care, these centers have evolved from traditional call centers to multi-functional patient support centers that specialize in handling medical-related communication needs, including appointment scheduling, prescription renewals, resource inquiries, and medical support work. The primary goal of these service centers is to ensure that patients receive timely and accurate medical support, and to enhance the patient experience through a multi-channel communication model that assists in personalizing the value of the treatment journey to improve medical outcomes.

In March this year, the “Cancer Series” art exhibition curated by the Fisher Museum of Art at the University of Southern California subverted the thinking of knowledge and science, by showcasing the physical and mental experience of artist Margaret Lazzari in the process of breast cancer treatment, not only attracted many art lovers and cancer patients to visit, but also created empathy and empathy in the exhibition, so that the general public can feel the heavy damage of breast cancer to people’s hearts and health threats, as well as the expectation of new treatments.

In modern businesses, the health and well-being of employees is an important cornerstone of a company’s success. The Employee Assistance Program (EAP) and Alternative Funding Program (AFP) in the U.S. offer companies an innovative way to help employees or their families access drug support beyond insurance. These programs combine multiple resources and funding sources to provide timely and effective medical support to employees, fulfilling SDs’ corporate health responsibilities.

In many cases, patients with serious or life-threatening illnesses cannot wait until a new drug is officially approved and marketed. For these patients, the Early Access Programs (EAP), Compassionate Use Programs (CUP), and Managed Access Programs (MAPs) provide an important treatment pathway. The content and main application methods of these schemes are different, and they are not the same as obtaining clinical trial drugs.

With the rapid development of modern society, unhealthy lifestyle has become an important cause of chronic diseases. In response to this challenge, President Lai Ching-te proposed the 888 Plan at the Healthy Taiwan Forum. The goal of the program is to bring 80% of patients with three highs (hypertension, hyperglycemia, and hyperlipidemia) into the care network in the next eight years, and allow 80% of them to receive lifestyle counseling, and eventually achieve a control rate of 80%. The program focuses not only on treatment, but also on prevention and lifestyle changes, with the aim of reducing the incidence and severity of chronic diseases.

PatientsForce Lighting Strategy Consultants have successfully completed the EcoVadis 2024 assessment and have been awarded the EcoVadis badge, ranking in the top 26% of other professional, scientific and technical industries in the world! Achieved an overall ranking of 55th on the EcoVadis Supplier Disclosure Platform. The assessment covers multiple aspects of corporate social responsibility, such as environment, labor and human rights, business ethics and sustainable procurement, especially in business ethics and labor human rights, and won the first EcoVadis Commitment Seal. EcoVadis is an independent assessment platform for supply chain transparency based on the ISO 26000 Corporate Social Responsibility standard, which is widely recognized by the world’s leading multinational companies.